Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 819   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2019  |  Volume : 36  |  Issue : 5  |  Page : 422-433

Pidotimod: In-depth review of current evidence

1 PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India
2 Department of Respiratory Medicine, Apollo Clinic, Chennai, Tamil Nadu, India
3 Department of Respiratory Medicine, Mehta Hospital, Ahmedabad, Gujarat, India
4 Department of Medical Affairs, Wockhardt Limited, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Ashok Mahashur
PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/lungindia.lungindia_39_19

Rights and Permissions

Pidotimod, an immunostimulant, is researched for over two decades. Current evidence indicates its utility in a variety of indications in children as well as in adults. Its immunostimulant activity has been firmly established in the management of recurrent respiratory infections in children with or without asthma. Compared to standard of care alone, addition of pidotimod to standard of care significantly prevents the recurrences and reduces the severity and duration of acute episodes, ultimately resulting in reduced visits to pediatric clinics and lower absenteeism at school. In adults, pidotimod is effective in the prevention and treatment of acute infectious exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD). Further, it has been evaluated in indications such as pneumonia, hand–food–mouth disease, bronchiectasis, and chronic idiopathic urticaria. From a total of 32 studies conducted in child (24 studies) and adult (8 studies) population, this in-depth review discusses the current evidence of pidotimod. With further exploration, the immunostimulant activity of pidotimod might be extended to different immunological disorders.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded454    
    Comments [Add]    

Recommend this journal